Compare Ascendis Pharma A/S (ASND) vs Sea Limited (SE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Sea Limited — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Sea Limited trades at $111.9 (market cap $68.07B). The key difference: Sea Limited is far larger — about 3.8× Ascendis Pharma A/S's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Sea Limited nearer its low. Which is the better fit depends on your goals.
| ASND | SE | |
|---|---|---|
Market Cap | $17.74B | $68.07B |
Sector | Health | Media |
52-Week High | $277.18 | $196.50 |
52-Week Low | $163.32 | $78.16 |
Enterprise Value | $18.11B | $61.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Sea Limited (SE) trades at $111.14, up 1.86% on the day, near its resistance level of $112. The stock shows strong revenue growth, with 2025 revenue reaching $22.94 billion and net income of $1.58 billion, though recent quarterly earnings have been mixed. Technical indicators are bullish on moving averages but show overbought conditions with RSI above 78. Analyst sentiment remains positive with a consensus price target of $131.
Outlook: Growth prospects are supported by expanding digital services in Southeast Asia, but risks include competitive pressures and execution challenges. The stock's high P/E of 43.76 suggests premium valuation, requiring sustained earnings growth to justify current levels. Near-term performance may hinge on Q2 2026 earnings versus expectations of $0.834 EPS.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Sea Limited
Sea Limited offers information technology services. The Company provides online personal computer and mobile digital content, e-commerce, and payment platforms. Sea serves customers worldwide.
Read more on SE →
